The discovery of mutations in isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) in over 80% of low-grade gliomas (LGGs) and secondary glioblastomas has revolutionized pharmaceutical approaches to targeted therapies and the overall glioma classification schema (1, 2). This evidence concerns the gene IDH2 and central nervous system cancer.